Navigation Links
Pressure BioSciences Closes Additional $745,000 of $5 Million PIPE; Funding Received to Date Exceeds $4,000,000
Date:11/17/2015

SOUTH EASTON, Mass., Nov. 17, 2015 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced it has received gross proceeds of $745,000 from an additional closing of its $5 million Private Placement (the "Offering"), increasing the total amount raised to date in the Offering to $4,025,000.  One or more additional closings are expected in the near future.

Pursuant to the Subscription Agreement, the Company will issue to the investors, Senior Secured Convertible Debentures with a fixed conversion price of $0.28 per restricted common share, and Common Stock Purchase Warrants exercisable into a total of 1,330,357 shares of restricted common stock at an exercise price of $0.40 per share. The Company is under no obligation to file a registration statement to register the shares underlying the Debentures and Warrants. The Company netted $670,500 in cash after taking into account fees related to the Offering.

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "The priorities for the use of funds from the Offering are as previously stated: (i) to expand the Company's marketing and sales capabilities, including a sizeable increase in the number of the Company's marketing and sales personnel; (ii) to increase the Company's manufacturing and operational capabilities; (iii) to ready the Company for a potential up-listing to a national regulated exchange in the near future, with the timing of the up-list based on market conditions and company valuation; and (iv) to retire all variable rate convertible debt ("VRCD") that had been previously taken on to help facilitate growth prior to additional equity capital being raised. It is expected that cash received from one or more additional closings that may occur in the near future will be used to eliminate all remaining VRCD debt, and to help the Company achieve our other specified goals."

This press release is not an offer to sell or a solicitation of offers to participate in the Offering. The units, including the shares underlying the Debentures and Warrants, have not been registered under the Securities Act and may not be sold in the United States absent registration under the Securities Act or an applicable exemption from registration.

For more information on the Offering, please see the Form 8-K filed by the Company on July 28, 2015.

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.

Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, in the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2015, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and TwitterInvestor Contacts: Richard T. Schumacher, President & CEO, PBI(508) 230-1828 (T)Jeffrey N. Peterson, Chairman, PBI(650) 812-8121 (T)Redwood Investment Group(714) 978-4425 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related biology news :

1. Research points to need for new approaches to treatment of high blood pressure
2. Dairy consumption linked to lower blood pressure and cardiovascular disease risk
3. Sodiums influence on blood pressure statistically insignificant
4. Super-parent cultural pressures can spur mental health conditions in new moms and dads
5. Eating lean beef daily can help lower blood pressure
6. Sensor in eye could track pressure changes, monitor for glaucoma
7. New cause of high blood pressure and heart disease discovered
8. Vegetarian diets associated with lower blood pressure
9. Punctured cell membranes lead to high blood pressure
10. Under pressure
11. Serengetis animals under pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2019)... SASKATOON, Canada (PRWEB) , ... February 12, 2019 ... ... immediately it will begin operating under its new name, KEYLEAF. The company ... more of its own plant-based extracts and ingredients as finished products under the ...
(Date:2/2/2019)... ... January 31, 2019 , ... ... , geared toward clinical operations executives and focusing on all facets of clinical ... effective project management, portfolio management, resource management, patient engagement, and more. , ...
(Date:1/25/2019)... ... January 24, 2019 , ... ... PhD, Assistant Professor of Microbiology at the Jackson Laboratory (JAX), to its Scientific ... world, Dr. Oh will bring to uBiome expertise in skin microbial interactions and ...
Breaking Biology News(10 mins):
(Date:1/30/2019)... , ... January 29, 2019 , ... ... (AskBio), today announced the dosing of the first patient in a phase 1/2 ... a serious disease associated with high morbidity and often leads to premature death. ...
(Date:1/30/2019)... WHITEHOUSE, N.J. (PRWEB) , ... January 30, 2019 ... ... brings together experts from pharma, academia and governmental agencies to discuss best practices ... Washington, DC from February 4-6. , At this year’s conference, Visikol will ...
(Date:1/28/2019)... SAN DIEGO (PRWEB) , ... January 28, 2019 ... ... proteins against libraries of low molecular weight compounds. In this early stage, false ... binding. At the same time, it is vital that screening techniques are highly ...
(Date:1/24/2019)... (PRWEB) , ... January 22, 2019 , ... ... since each trial has its own set of assumptions, and RFP creation and ... so evaluating bids is like comparing apples to oranges. These challenges can ultimately ...
Breaking Biology Technology: